27 research outputs found
Recommended from our members
Heritage Reproduction in the Age of High-Resolution Scanning:A Critical Evaluation of Digital Infilling Methods for Historic Preservation
High-definition digital scanning has established itself as a useful tool for documenting cultural heritage in the twenty-first century. Proponents of surveying technology are hailing the use of digital fact-based 3D models as valuable tools for recording, analyzing and safeguarding items of cultural importance. Methods for digitally filling holes have not yet been considered through the lens of historic preservation. No modeling technique is error-free and understanding how heritage professionals are addressing lacunae is vital for understanding digital heritage objects resulting from 3D scanning hardware. Frameworks exist for working with scanned data, but they define general principles for a broad range of applications and do not provide any guidelines or strategies of how to comply with them practically. This thesis is a comparative evaluation of current practices of in-filling digital lacunae that attempts to establish which methods are best suited to the following historic preservation practices: documentation, Interpretation graphics, Long-term monitoring, digital restoration, physical fabrication
Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016
The UN’s Sustainable Development Goals (SDGs) are grounded in the global ambition of “leaving no one behind”. Understanding today’s gains and gaps for the health-related SDGs is essential for decision makers as they aim to improve the health of populations. As part of the Global Burden of Diseases, Injuries, and Risk Factors Study 2016 (GBD 2016), we measured 37 of the 50 health-related SDG indicators over the period 1990–2016 for 188 countries, and then on the basis of these past trends, we projected indicators to 2030
Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015:a systematic analysis for the Global Burden of Disease Study 2015
Background Healthy life expectancy (HALE) and disability-adjusted life-years (DALYs) provide summary measures of health across geographies and time that can inform assessments of epidemiological patterns and health system performance, help to prioritise investments in research and development, and monitor progress toward the Sustainable Development Goals (SDGs). We aimed to provide updated HALE and DALYs for geographies worldwide and evaluate how disease burden changes with development.Methods We used results from the Global Burden of Diseases, Injuries, and Risk Factors Study 2015 (GBD 2015) for all-cause mortality, cause-specific mortality, and non-fatal disease burden to derive HALE and DALYs by sex for 195 countries and territories from 1990 to 2015. We calculated DALYs by summing years of life lost (YLLs) and years of life lived with disability (YLDs) for each geography, age group, sex, and year. We estimated HALE using the Sullivan method, which draws from age-specific death rates and YLDs per capita. We then assessed how observed levels of DALYs and HALE differed from expected trends calculated with the Socio-demographic Index (SDI), a composite indicator constructed from measures of income per capita, average years of schooling, and total fertility rate.Findings Total global DALYs remained largely unchanged from 1990 to 2015, with decreases in communicable, neonatal, maternal, and nutritional (Group 1) disease DALYs off set by increased DALYs due to non-communicable diseases (NCDs). Much of this epidemiological transition was caused by changes in population growth and ageing, but it was accelerated by widespread improvements in SDI that also correlated strongly with the increasing importance of NCDs. Both total DALYs and age-standardised DALY rates due to most Group 1 causes significantly decreased by 2015, and although total burden climbed for the majority of NCDs, age-standardised DALY rates due to NCDs declined. Nonetheless, age-standardised DALY rates due to several high-burden NCDs (including osteoarthritis, drug use disorders, depression, diabetes, congenital birth defects, and skin, oral, and sense organ diseases) either increased or remained unchanged, leading to increases in their relative ranking in many geographies. From 2005 to 2015, HALE at birth increased by an average of 2.9 years (95% uncertainty interval 2.9-3.0) for men and 3.5 years (3.4-3.7) for women, while HALE at age 65 years improved by 0.85 years (0.78-0.92) and 1.2 years (1.1-1.3), respectively. Rising SDI was associated with consistently higher HALE and a somewhat smaller proportion of life spent with functional health loss; however, rising SDI was related to increases in total disability. Many countries and territories in central America and eastern sub-Saharan Africa had increasingly lower rates of disease burden than expected given their SDI. At the same time, a subset of geographies recorded a growing gap between observed and expected levels of DALYs, a trend driven mainly by rising burden due to war, interpersonal violence, and various NCDs.Interpretation Health is improving globally, but this means more populations are spending more time with functional health loss, an absolute expansion of morbidity. The proportion of life spent in ill health decreases somewhat with increasing SDI, a relative compression of morbidity, which supports continued efforts to elevate personal income, improve education, and limit fertility. Our analysis of DALYs and HALE and their relationship to SDI represents a robust framework on which to benchmark geography-specific health performance and SDG progress. Country-specific drivers of disease burden, particularly for causes with higher-than-expected DALYs, should inform financial and research investments, prevention efforts, health policies, and health system improvement initiatives for all countries along the development continuum. Copyright (C) The Author(s). Published by Elsevier Ltd.</p
Fermentation du glycérol chez des propionibactéries et optimisation de la production d'acide propionique
Correspondance: [email protected] audienceLa fermentation du glycérol en acide propionique a été étudiée comparativement à celle du glucose chez deux propionibactéries: P. acidipropionici et P. freudenreichii ssp sherrnanii. P. acidipropionici a montré un rendement très élevé en acide propionique (0,79 mol/mol) et sa capacité à produire une forte concentration en acide propionique (42 g/I) en fermentation batch. Parallèlement, la très faible production d'acide acétique a été mise en évidence au cours de la fermentation du glycérol. Le ratio molaire acide propionique/acide acétique (P/A) qui est particulièrement élevé au cours de la fermentation du glycérol par P. acidipropionici: P/A= 88 en fermentation continue et 5,5 en fermentation batch, a suggéré l'hypothèse de l'orientation homopropionique de la fermentation du glycérol. L'étude en fermentation continue par cellules immobilisées (alginate de calcium) a permis d'obtenir une très forte productivité en acide propionique (3 g/l,h) avec un rendement de 0,78 mol/mol. Ces très hautes performances soulignent les nouvelles perspectives d'optimisation de la production d'acide propionique par fermentatio
Effect of fabric architecture, compaction and permeability on through thickness thermoplastic melt impregnation
To reduce the cycle time of structural, automotive thermoplastic composites, we investigated the potential of direct thermoplastic melt impregnation of glass fabrics using an injection moulding process. At the high pressures that occur during the process, the effect of the fabric architecture on the impregnation, compaction, volume fraction and permeability of two unidirectional fabrics was studied. Using impregnation experiments with a low viscosity PA6 melt, we identified a favourable processing window resulting in an impregnation time of 5 min. The impregnation experiments with thermoplastic melts demonstrate that textile architectures promoting dual scale flow during impregnation are favourable for complete filling. Based on our findings, thermoplastic compression resin transfer moulding is an efficient processing route for automated production of composite parts with a high fibre volume fraction, if the fabric architecture is adapted for higher processing pressures and by fully utilising dual scale flow.Aerospace Manufacturing Technologie
Stable Isotope Techniques for the Assessment of Host and Microbiota Response During Gastrointestinal Dysfunction
The International Atomic Energy Agency convened a technical meeting on environmental enteric dysfunction (EED) in Vienna (October 28–30, 2015; https://nucleus.iaea.org/HHW/Nutrition/EED_Technical_Meeting/index.html) to bring together international experts in the fields of EED, nutrition, and stable isotope technologies. Advances in stable isotope–labeling techniques open up new possibilities to improve our understanding of gastrointestinal dysfunction and the role of the microbiota in host health. In the context of EED, little is known about the role gut dysfunction may play in macro- and micronutrient bioavailability and requirements and what the consequences may be for nutritional status and linear growth. Stable isotope labeling techniques have been used to assess intestinal mucosal injury and barrier function, carbohydrate digestion and fermentation, protein-derived amino acid bioavailability and requirements, micronutrient bioavailability and to track microbe-microbe and microbe-host interactions at the single cell level. The noninvasive nature of stable isotope technologies potentially allow for low-hazard, field-deployable tests of gut dysfunction that are applicable across all age groups. The purpose of this review is to assess the state-of-the-art use of stable isotope technologies and to provide a perspective on where these technologies can be exploited to further our understanding of gut dysfunction in EED.ISSN:0277-2116ISSN:1536-480
Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.
Importance: Eritoran is a synthetic lipid A antagonist that blocks lipopolysaccharide (LPS) from binding at the cell surface MD2-TLR4 receptor. LPS is a major component of the outer membrane of gram-negative bacteria and is a potent activator of the acute inflammatory response. Objective: To determine if eritoran, a TLR4 antagonist, would significantly reduce sepsis-induced mortality. Design, Setting, and Participants: We performed a randomized, double-blind, placebo-controlled, multinational phase 3 trial in 197 intensive care units. Patients were enrolled from June 2006 to September 2010 and final follow-up was completed in September 2011. Interventions: Patients with severe sepsis (n=1961) were randomized and treated within 12 hours of onset of first organ dysfunction in a 2:1 ratio with a 6-day course of either eritoran tetrasodium (105 mg total) or placebo, with n=1304 and n=657 patients, respectively. Main Outcome Measures: The primary end point was 28-day all-cause mortality. The secondary end points were all-cause mortality at 3, 6, and 12 months after beginning treatment. Results: Baseline characteristics of the 2 study groups were similar. In the modified intent-to-treat analysis (randomized patients who received at least 1 dose) there was no significant difference in the primary end point of 28-day all-cause mortality with 28.1% (366/1304) in the eritoran group vs 26.9% (177/657) in the placebo group (P=.59; hazard ratio, 1.05; 95% CI, 0.88-1.26; difference in mortality rate, -1.1; 95% CI, -5.3 to 3.1) or in the key secondary end point of 1-year all-cause mortality with 44.1% (290/657) in the eritoran group vs 43.3% (565/1304) in the placebo group, Kaplan-Meier analysis of time to death by 1 year, P=.79 (hazard ratio, 0.98; 0.85-1.13). No significant differences were observed in any of the prespecified subgroups. Adverse events, including secondary infection rates, did not differ between study groups. Conclusions and Relevance: Among patients with severe sepsis, the use of eritoran, compared with placebo, did not result in reduced 28-day mortality. Trial Registration: clinicaltrials.gov Identifier: NCT0033482